The FDA has approved baricitinib for adolescents aged 12 and older with severe alopecia areata, marking the first systemic oral therapy cleared for this population.
|Slideshows|April 7, 2022
7 New Drugs Approved for Primary Care: Q1 2022
Author(s)Sydney Jennings
Advertisement
At the close of the first quarter of a new year, Patient Care Online has compiled a list of 7 new FDA-approved drugs for conditions that are often seen in primary care. Scroll through the slides below to find details on a new oral solution of amlodipine; the first and only FDA-approved, once-daily amphetamine transdermal patch for the treatment of attention deficit hyperactivity disorder; and 5 more.
Advertisement
Related to this article
FDA approves olanzapine, a once-monthly subcutaneous injection for adults with schizophrenia, boosting symptom control while reducing monitoring needs and highlighting weight risks.
FDA has granted IDE approval for the STROKE-REWIRE pivotal trial evaluating NeuWire Medical's neurostimulation device for chronic ischemic stroke recovery.
Catch up on the 9 FDA drug approvals most relevant to primary care, including new options for HIV-1 infection, narcolepsy, diabetes, pain management, and more.
September FDA news included updates in CKD and type 1 diabetes, major depressive disorder, insulin pump technology, alopecia areata, and more.
EADV 2026: Lebrikizumab improved hand and foot clearance, itch, and pain at 16 weeks versus placebo in a phase 3b atopic dermatitis trial.
The FDA accepted Bayer's sNDA and granted Priority Review to elinzanetant for vasomotor symptoms in women on endocrine therapy for HR+ breast cancer.
The FDA has approved insulin efsitora alfa-gobe (Onswik) for adults with type 2 diabetes.
Advertisement
Advertisement
Trending on Patient Care Online
1
Menopause Hormone Therapy Linked to Greater Weight Loss With Semaglutide in Real-World Study
2
Fezolinetant May Improve Depression, Anxiety Symptoms in Women With Menopausal VMS
3
Capsule-Sponge Testing Could Help Close the Barrett’s Screening Gap: An Expert Q&A
4
AI-Enhanced Virtual Reality Program Delivering CBT Shows Early Feasibility for Menopause Symptoms: TMS 2026
5